The FDA’s Oncologic Drugs Advisory Committee review of camizestrant SERENA-6 places one of the most important questions in modern breast oncology directly in front of regulators: should a molecular signal of endocrine resistance be enough to change treatment before scans show progression?
This is not a routine oral SERD review. SERENA-6 tests a new treatment paradigm in HR-positive, HER2-negative advanced breast cancer: serial ctDNA monitoring for emerging ESR1 mutations, followed by an early switch from an aromatase inhibitor to camizestrant while continuing CDK4/6 inhibition. The trial clearly met its primary endpoint, showing a progression-free survival advantage for the early-switch strategy. The more difficult regulatory question is whether that PFS benefit, measured from the moment of ESR1 mutation detection rather than radiographic progression, establishes a favorable long-term benefit-risk profile for patients with incurable disease.
A New Treatment Paradigm Under FDA Review
Camizestrant, also known as AZD9833, is described by AstraZeneca as a next-generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist. The proposed indication is camizestrant in combination with a CDK4/6 inhibitor, including palbociclib, ribociclib, or abemaciclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer upon emergence of an ESR1 mutation during first-line endocrine-based therapy. The FDA briefing document notes that the agency refers to camizestrant as an oral estrogen receptor antagonist rather than a selective estrogen receptor degrader, because “estrogen receptor antagonist” is the established pharmacologic class for drugs such as camizestrant.
The purpose of the ODAC meeting is to discuss whether camizestrant plus CDK4/6 inhibition has established a favorable benefit-risk profile based on SERENA-6. The FDA emphasizes that no current drug is approved for switching treatment based only on ESR1 mutation detection before radiographic progression, making the clinical interpretation of this strategy especially important.
Why ESR1 Mutation Detection Matters
HR+/HER2− advanced breast cancer remains the most common subtype of metastatic breast cancer. The briefing document notes that approximately 70% of patients present with HR-positive, HER2-negative disease, and that advanced disease remains incurable, with treatment goals focused on delaying progression, preserving quality of life, delaying chemotherapy, and prolonging survival.
First-line endocrine therapy with an aromatase inhibitor plus a CDK4/6 inhibitor is now a dominant standard for endocrine-sensitive HR+/HER2− advanced breast cancer. However, resistance eventually develops. One of the best-characterized mechanisms is emergence of ESR1 mutations, which can make aromatase inhibition biologically ineffective by activating the estrogen receptor independent of estrogen. The applicant states that ESR1 mutation prevalence rises from approximately 4% at initial diagnosis of HR+/HER2− advanced breast cancer to around 40% at the end of first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, and may exceed 50% among patients treated for more than one year.
This creates the scientific rationale for SERENA-6. If ESR1 mutation is detected while the patient has not yet progressed radiographically, continuing the same aromatase inhibitor may mean maintaining a treatment backbone against which the tumor is already developing resistance. Camizestrant offers a way to replace that endocrine backbone earlier, while preserving CDK4/6 inhibition.
How SERENA-6 Was Designed
SERENA-6 was a randomized, double-blind, placebo-controlled, two-part clinical trial. Patients with ER-positive, HER2-negative advanced breast cancer who had received an aromatase inhibitor plus a CDK4/6 inhibitor for at least six months underwent serial ctDNA testing every two to three months. Patients with a detected ESR1 mutation and no radiographic or clinical progression were then eligible for randomization.
In the randomized part of the trial, patients were assigned 1:1 to either switch endocrine therapy to camizestrant while continuing the same CDK4/6 inhibitor or continue aromatase inhibitor plus CDK4/6 inhibitor. The primary endpoint was progression-free survival, defined from randomization at ESR1 mutation detection to radiographic progression or death. PFS2 and overall survival were key secondary endpoints.
This design is the central strength and the central controversy of the trial. It directly tests whether molecular progression can be used as an actionable clinical timepoint. But it also changes how PFS is interpreted, because the clock starts before traditional radiographic progression.
Read About SERENA-6 Trial on OncoDaily
A Clear PFS Benefit
SERENA-6 met its primary endpoint. At the prespecified interim analysis, switching to camizestrant while continuing CDK4/6 inhibition reduced the risk of disease progression or death by 56% compared with continuing aromatase inhibitor plus CDK4/6 inhibitor. Median PFS was 16.0 months with camizestrant plus CDK4/6 inhibitor versus 9.2 months with continued aromatase inhibitor plus CDK4/6 inhibitor, with a hazard ratio of 0.44 and a 95% confidence interval of 0.31–0.60. The blinded independent central review result was similar, with an HR of 0.43.
With longer follow-up at the third data cutoff, additional PFS2 and OS events were available. The study had multiple planned data cutoffs, with DCO1 in November 2024, DCO2 in June 2025, DCO3 in January 2026, and a final OS analysis pending. At DCO3, median follow-up had increased to approximately 23.5 months, and OS maturity remained 30%.
From an efficacy standpoint, the PFS result is clinically interesting and statistically robust. It also supports a broader idea increasingly relevant in breast oncology: that ctDNA may identify resistance before imaging does. But regulatory approval requires more than a statistically positive endpoint, especially when the endpoint is measured from a novel timepoint.
Why The FDA Remains Cautious
The FDA’s main concern is not whether camizestrant improved PFS in SERENA-6. It did. The agency’s concern is whether early switching at ESR1 mutation detection is better for patients than the current standard approach of changing therapy when radiographic progression occurs.
The FDA notes that SERENA-6 was not designed to prove that switching at ESR1 mutation detection is superior to switching at radiographic progression. No crossover to camizestrant plus CDK4/6 inhibitor was permitted for patients in the control arm at progression. The FDA also points out that patients who continued aromatase inhibitor plus CDK4/6 inhibitor after ESR1 mutation detection remained on that regimen for a median of 9.2 months before progression or death. This raises a clinically important question: does early switching improve long-term outcomes, or does it shorten the useful duration of a still-active treatment line?
The second issue is the meaning of PFS itself. In most first-line metastatic breast cancer trials, PFS starts at diagnosis of advanced disease or treatment initiation. In later-line trials, it starts after radiographic progression, when a new treatment is clearly needed. SERENA-6 starts at molecular detection of ESR1 mutation, and the FDA states that the clinical meaningfulness of a PFS improvement measured from that point is uncertain.
PFS2 And OS Add Complexity
SERENA-6 also met its PFS2 endpoint. At DCO3, median PFS2 was 25.7 months with camizestrant plus CDK4/6 inhibitor versus 19.1 months with continued aromatase inhibitor plus CDK4/6 inhibitor, corresponding to a hazard ratio of 0.63 and a 95% confidence interval of 0.46–0.86.
However, the FDA does not consider PFS2 adequate for regulatory decision-making in this setting. The agency’s reasoning is that PFS2 does not isolate the effect of the experimental drug, depends on subsequent therapy choice and timing, and may be influenced by regional availability, local standards, and investigator discretion. In SERENA-6, it also does not answer the core question of whether switching at ESR1 mutation detection is better than switching at radiographic progression, because the trial was not designed to compare those two strategies directly.
Overall survival is not yet mature. At DCO3, OS maturity was approximately 30%, with final OS analysis not expected until around 2028. The FDA states that OS could help resolve uncertainty about long-term benefit, but the trial may be underpowered to demonstrate statistical significance for OS.
Read About Camizestrant on OncoDaily
Safety: Visual Disturbances, Bradycardia, And QT Risk
Safety is another key part of the ODAC discussion. The FDA briefing document describes camizestrant’s safety profile as generally consistent with endocrine therapy plus CDK4/6 inhibition, but with additional toxicities of visual disturbances, bradycardia, and QT prolongation.
Visual disturbances were more common with camizestrant. The FDA included visual field defect and decreased visual acuity in its grouped term, resulting in visual disturbances of any grade in 34% of patients receiving camizestrant plus CDK4/6 inhibitor versus 16% with aromatase inhibitor plus CDK4/6 inhibitor. Photopsia was the most common event, occurring in 20% versus 8%, respectively. Most visual events were grade 1 or 2, with one grade 3 photopsia case reported.
Bradycardia was also noted. In SERENA-6, bradycardia grouped terms occurred in 7.7% of patients receiving camizestrant plus CDK4/6 inhibitor and 0% in the control arm. The FDA notes that camizestrant is associated with a median heart rate decrease of about 14 beats per minute and that this may increase the risk of clinically significant bradycardia in patients with low baseline heart rate.
The most serious safety concern involves the potential interaction between bradycardia and QT prolongation, particularly with ribociclib. The FDA states that camizestrant has heart rate lowering and QT-prolonging effects, and that coadministration with QT-prolonging drugs such as ribociclib may increase arrhythmia risk. One patient in the phase 1 SERENA-1 trial who received camizestrant plus ribociclib at doses used in SERENA-6 developed bradycardia, QT prolongation, and torsades de pointes. Only 23 patients in SERENA-6 received camizestrant plus ribociclib, limiting assessment of that specific combination.
What The ODAC Decision Could Mean
The camizestrant SERENA-6 review is bigger than one drug. It is a test case for whether oncology can move from treating radiographic progression to treating molecular resistance. If the benefit-risk assessment is viewed favorably, SERENA-6 may open the door for ctDNA-guided adaptive treatment in HR+/HER2− metastatic breast cancer. If the FDA remains unconvinced, future trials may need to directly compare early molecular switching with switching at radiographic progression.
For clinicians, the trial already reinforces the importance of ESR1 mutation monitoring and the biological relevance of endocrine resistance during first-line AI plus CDK4/6 inhibitor therapy. But the unresolved question is how early oncologists should act on that information. A molecular signal may be real, but whether acting earlier improves long-term patient outcomes remains the central debate.
Key Takeaway
SERENA-6 showed that switching from an aromatase inhibitor to camizestrant while continuing CDK4/6 inhibition significantly prolonged PFS in patients with emerging ESR1-mutated HR+/HER2− advanced breast cancer before radiographic progression. The FDA’s concern is whether this early-switch strategy has proven long-term benefit, especially with immature OS, uncertainty around PFS2, and specific safety issues including bradycardia, QT risk, and visual disturbances.
The ODAC discussion will help define whether ctDNA-guided endocrine switching becomes a new clinical standard or remains an important hypothesis requiring a more definitive trial design.
Read Also About Oral SERDs on OncoDaily